Abstract

BackgroundIt is presently unclear whether glycemic variability is associated with diabetic cardiovascular autonomic neuropathy (CAN). The aim of this study was to examine whether short- and/or long-term glycemic variability (GV) contribute to CAN.MethodsA total of 110 patients with type 2 diabetes who underwent three-day continuous glucose monitoring (CGM) completed five standardized autonomic neuropathy tests. Short-term GV was measured by the standard deviation (SD), coefficient of variation (CV) of glucose, and the mean amplitude of glycemic excursions (MAGE) in CGM. HbA1c variability was calculated from the intrapersonal SD, adjusted SD, and CV of serial HbA1c over 2-year period. CAN was defined as the presence of at least two abnormal parasympathetic function tests. The severity of CAN was evaluated by total scores of five autonomic function tests.ResultsIn univariate analysis, not only SD and CV in CGM but also all parameters of HbA1c variability were significantly higher in the patients with CAN (n = 47, 42.7 %) than in those without CAN. In multivariate analysis, CV (Odds ratio [OR] 1.07, 95 % confidence interval [CI] 1.01–1.13; p = 0.033), but neither SD nor MAGE in CGM, independently correlated with the presence of CAN. All parameters of HbA1c variability, such as SD of HbA1c (OR 12.10 [95 % CI 2.29–63.94], p = 0.003), adjusted SD of HbA1c (OR 17.02 [95 % CI 2.66–108.86], p = 0.003), and log CV of HbA1c (OR 24.00 [95 % CI 3.09–186.48], p = 0.002), were significantly associated with the presence of CAN. The patients with higher HbA1c variability had an increased risk of advanced CAN.ConclusionCV in CGM and all parameters of HbA1c variability were independently associated with the presence of CAN in patients with inadequately controlled type 2 diabetes requiring CGM.Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-015-0233-0) contains supplementary material, which is available to authorized users.

Highlights

  • It is presently unclear whether glycemic variability is associated with diabetic cardiovascular autonomic neuropathy (CAN)

  • Complications Trial (DCCT) using seven-point selfmonitoring blood glucose (SMBG) levels revealed no significant association between short-term glycemic variability (GV) and diabetic retinopathy, nephropathy [6], or neuropathy, which was defined as abnormal nerve conduction, sensory signs, and heart rate variability in type 1 diabetes [7]

  • The comparison of glycemic parameters between patients with and without CAN continuous glucose monitoring (CGM) parameters except mean amplitude of glycemic excursions (MAGE) were significantly higher in CAN group

Read more

Summary

Introduction

It is presently unclear whether glycemic variability is associated with diabetic cardiovascular autonomic neuropathy (CAN). The aim of this study was to examine whether short- and/or long-term glycemic variability (GV) contribute to CAN. Diabetic cardiovascular autonomic neuropathy (CAN) is one of several common diabetic microvascular complications. Complications Trial (DCCT) using seven-point selfmonitoring blood glucose (SMBG) levels revealed no significant association between short-term GV and diabetic retinopathy, nephropathy [6], or neuropathy, which was defined as abnormal nerve conduction, sensory signs, and heart rate variability in type 1 diabetes [7]. The Epidemiology of Diabetes Interventions and Complications (EDIC) study, which was extended from the DCCT, found no evidence of a contribution of short-term GV to retinopathy or nephropathy [8]. One of the limitations in those studies was that the seven-point glucose profiles did not adequately reflect overall glycemic patterns

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call